Infirst Healthcare USA

What Infirst Healthcare USA does

Infirst Healthcare Inc. is a privately held U.S. consumer healthcare company founded in 2013 and headquartered in Westport, CT, that develops and commercializes over-the-counter medicines and distributed medical devices under a multi-brand portfolio organized around four pillars. Its own or exclusively licensed brands include Mylanta (the #1-selling and #1 doctor-recommended liquid antacid, spanning liquids, chewable tablets, and gas-mini formats), Mylicon (the #1-selling and #1 pediatrician-recommended infant gas relief brand, extended into probiotic drops and children's tummy relief), and Dr. Cocoa (a pediatric cough-and-cold line built around real cocoa). The company holds exclusive U.S. commercialization rights to Mylanta and Mylicon under license from McNeil Consumer Pharmaceuticals Company. In 2019 it extended beyond OTC into medical devices by taking on U.S. distribution of Ypsomed's Orbit infusion sets and Clickfine pen needles for diabetes care, and in 2021 it launched ECOCARE, an infinitely recyclable aluminum bottle platform intended as the first of a pipeline of sustainable packaging innovations for OTC medicines.

The company operates with a sales-led go-to-market, combining a direct sales force and broker network to ship product from its own warehouse and logistics facility in Plainfield, IN to more than 70 top-tier U.S. retailers across pharmacy, grocery, and mass channels. End customers are individual consumers — adults with heartburn and gas, infants and children with digestive or cough/cold symptoms, and diabetes patients needing infusion sets and pen needles. Marketing is primarily brand-portfolio-website driven, supplemented by LinkedIn presence and cookie-based digital advertising. Leadership is led by founder and CEO James Barickman, supported by a CCO with prior GSK consumer healthcare experience, a VP Finance, and a General Counsel, reflecting a deliberately compact team of consumer healthcare, sales, and CPG-operations professionals rather than a technology platform organization. Revenue mechanics are wholesale hardware/product sales through retail and broker channels; pricing is not publicly disclosed.

Name

Infirst Healthcare USA

Legal name

Infirst Healthcare Inc.

Website

https://infirst-usa.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Infirst Healthcare USA is a privately held consumer healthcare company founded in 2013 that develops and commercializes OTC brands — Mylanta, Mylicon, and Dr. Cocoa — under license from McNeil, and distributes Ypsomed medical devices, selling through 70+ top-tier U.S. retailers.

Ownership category

akta.pro rank

Product category

Consumer Healthcare Products

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYCRADAMAD

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

SECONDARYCRAFAHAG

Medical, Dental & Lab Supply Marketplaces

Consumer Products & Retail/E-commerce & Marketplaces/Wholesale/B2B E-commerce Marketplaces

Keywords

• Consumer healthcare products
• Over-the-counter medicines
• Antacid products
• Infant gas relief
• Medical device distribution

Headquarters

HQ city

Westport

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D

Revenue model

1. OTC Consumer Healthcare Products: Infirst Healthcare generates revenue through the sale of over-the-counter healthcare products including Mylanta antacids, Mylicon infant gas relief products, and Dr. Cocoa pediatric cough and cold products. These are sold through retail channels to consumers.
2. Medical Devices Distribution: Distribution of Ypsomed Orbit brand infusion sets and Clickfine brand pen needles to the U.S. market. Medical devices for diabetes care patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Infirst Healthcare develops, brands, and commercializes over-the-counter consumer healthcare products (Mylanta antacids, Mylicon infant gas relief, Dr. Cocoa pediatric cough and cold) and distributes partnered medical devices (Ypsomed Orbit infusion sets and Clickfine pen needles) for the U.S. retail healthcare market. The company operates a multi-brand portfolio across adult, pediatric, and infant segments, selling through over 70 top-tier retailers via direct and broker sales channels from its Plainfield, IN warehouse.

Product overview

Infirst Healthcare USA is a consumer healthcare company that develops and commercializes healthcare products and medical devices. The company operates a multi-brand portfolio of over-the-counter medicines organized around four core pillars: Mylanta® (antacid liquids, tablets, and gas relief products for adults), Mylicon® (infant gas relief drops, probiotic drops, and children's tummy relief), Dr. Cocoa® (pediatric cough and cold products), and distributed Ypsomed medical devices (Orbit® infusion sets and Clickfine® pen needles for diabetes care). The company also innovates in sustainable packaging with its ECOCARE® aluminum bottle technology. The portfolio targets consumers across life stages from infants to adults, serving both retail and professional channels through a network of over 70 top-tier retailers.

Differentiator

Problem solved

Functional benefit

Brands

• Mylanta: #1-selling and #1 doctor-recommended liquid antacid brand for heartburn, acid indigestion, and gas relief. Products include Mylanta Liquids, Mylanta ONE tablets, and Mylanta Gas Minis.
• Mylicon
• Dr. Cocoa
• Ypsomed Orbit
• Clickfine
• ECOCARE

Products and services

• Mylanta Liquids Multi-symptom liquid antacid that works on contact to neutralize acid, providing fast relief of heartburn, acid indigestion, sour stomach, bloating and gas; available in four great-tasting formulations for adult consumers.
• Mylanta ONE Tablets All-in-one chewable tablets combining three ingredients for fast, multi-symptom relief of heartburn, acid indigestion, and bloating from gas; for adult consumers.
• Mylanta Gas Minis Extra-strength gas relief tablets in convenient mini format with on-the-go pocket-pack packaging, available in two great-tasting flavors for adult consumers.
• Infants' Mylicon Gas Relief Infant gas relief drops that work gently to speed up a baby's natural process of getting rid of gas, relieving pressure and discomfort; not absorbed into the bloodstream, safe for newborns; the #1-selling and #1 pediatrician-recommended infant gas relief brand.
• Infants' Mylicon Daily Probiotic Drops Clinically supported colic-relief probiotic drops that help reduce crying and fussiness associated with colic when used daily, promoting healthy gut bacteria and immune system support for infants.
• Children's Mylicon Tummy Relief All-in-one tummy relief medicine for children ages 2-11 with two fast-acting ingredients treating multiple causes of tummy discomfort, available as cherry-flavored chewable tablets or bubble-gum flavored liquid.
• Dr. Cocoa Pediatric cough and cold products made with real cocoa for soothing, multi-symptom relief with a great chocolate taste, marketed as 'Relief with a Smile' for children.
• Orbit Infusion Sets High-quality medical device infusion sets distributed to the U.S. market by Infirst Healthcare under the Ypsomed Orbit brand, designed for enhanced patient comfort, ease of use, and freedom of movement for diabetes care patients.
• Clickfine Pen Needles High-quality medical device pen needles distributed to the U.S. market by Infirst Healthcare under the Ypsomed Clickfine brand, designed for enhanced patient comfort, ease of use, and freedom of movement for diabetes care patients.

Quantifiable outcome

• Mylanta is the #1-selling and #1 doctor-recommended liquid antacid brand in the U.S.
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• YpsomedcoreChannel Partner/ Reseller/ DistributorInfirst Healthcare distributes Ypsomed Orbit brand infusion sets and Clickfine brand pen needles to the U.S. market. High-quality medical device design and craftsmanship deliver enhanced patient comfort, ease of use, and freedom of movement for diabetes patients.

Scale indicators2 records

Recent moves2 records

Expansion highlights4 records

Broad incumbents

• Procter & Gamble (P&G Health): Through its Health division, P&G markets OTC brands such as Pepto-Bismol and Vicks; an established large-scale U.S. consumer healthcare competitor across overlapping categories.
• Haleon: Spun out of GSK Consumer Healthcare, Haleon is one of the world's largest dedicated consumer health companies spanning oral care, digestive health and cough/cold — the categories where Mylanta and Dr. Cocoa compete.
• Bayer Consumer Health: Operates a global OTC consumer health business that competes in digestive (e.g., Alka-Seltzer, Pepto) and cough/cold categories where Infirst's Mylanta and Dr. Cocoa brands are positioned.
• Church & Dwight: Major U.S. CPG player with a leading OTC and personal-care portfolio; directly competes in adjacent over-the-counter categories on similar U.S. mass and drugstore shelves.
• Reckitt Benckiser: Global consumer health company with leading OTC positions in digestive (Gaviscon, Mucinex) and infant/children's health — competing directly against Mylanta, Mylicon and Dr. Cocoa.

Others

• Ypsomed Holding: Swiss medical-device manufacturer of the Orbit infusion sets and Clickfine pen needles that Infirst distributes in the United States; a strategic supplier-partner rather than competitor.
• McNeil Consumer Pharmaceuticals: Licensor of Mylanta and Mylicon trademarks to Infirst; also a historical OTC manufacturer. The licensing relationship and its renewal/strategic direction are central to Infirst's brand portfolio risk.

Direct peers

• Embecta: Spun off from Becton Dickinson to focus on diabetes injection devices including pen needles — directly comparable to Infirst's distribution of Ypsomed's Clickfine pen needles in the U.S. diabetes care market.
• Prestige Consumer Healthcare: U.S.-focused OTC consumer healthcare company that acquires, markets and distributes established OTC brands — directly comparable in operating model to Infirst's licensing/brand-management approach for legacy OTC assets.

Emerging players

• Pfizer Consumer Healthcare (now Haleon): Historically a major OTC brand owner (now largely Haleon) — included as an emerging/broad peer reflecting the McNeil/J&J historical ecosystem in which Mylanta and Mylicon originated and were exchanged between major consumer health players.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/infirst/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Infirst Healthcare USA